Index,NCTId,Condition,Change,Reference,Variable,Timepoint,Endpoint Art
0,NCT01814787,Type 2 Diabetes,Number of Children,Not Mentioned,Documented Risk Factors,Not Mentioned,Primary_endpoint
1,NCT01346033,Type 2 Diabetes,Not Mentioned,Validation,SCOUT DS algorithm,Not Mentioned,Primary_endpoint
2,NCT04765631,Type 2 Diabetes,outcome,comparison,total volumetric bone mineral density (vBMD),Not Mentioned,Primary_endpoint
3,NCT03979768,Type2 Diabetes,Number of Participants,Not Mentioned,Not Mentioned,Not Mentioned,Primary_endpoint
4,NCT03979768,Type2 Diabetes,number of participants,Not Mentioned,HbA1c-measurement (HbA1c-group),Not Mentioned,Secondary_endpoint
5,NCT02286128,Type 2 Diabetes,Not Mentioned,Correlation,osteoblast-specific gene expression in the MSC,Not Mentioned,Primary_endpoint
6,NCT02286128,Type 2 Diabetes,Not Mentioned,Correlation,NF-кB dependent-proinflammation markers,Not Mentioned,Secondary_endpoint
7,NCT02286128,Type 2 Diabetes,Not Mentioned,Correlation,NF-кB dependent-proinflammation markers,Not Mentioned,Secondary_endpoint
8,NCT03362762,Type 2 Diabetes Treated With Insulin,Characteristic,patients,insulin,Not Mentioned,Primary_endpoint
9,NCT03362762,Type 2 Diabetes Treated With Insulin,Not Mentioned,relation,plan of insulinothérapie,Not Mentioned,Secondary_endpoint
10,NCT01920256,Type 2 Diabetes,Change,baseline,A1C (glycated hemoglobin),12 months,Primary_endpoint
11,NCT01920256,Type 2 Diabetes,Change,baseline,lipids,12 months,Secondary_endpoint
12,NCT01920256,Type 2 Diabetes,Change,baseline,blood pressure,12 months,Secondary_endpoint
13,NCT01920256,Type 2 Diabetes,Not Mentioned,Not Mentioned,Not Mentioned,All cause,Secondary_endpoint
14,NCT01920256,Type 2 Diabetes,Not Mentioned,Not Mentioned,Acute complications,Not Mentioned,Secondary_endpoint
15,NCT01920256,Type 2 Diabetes,Change,baseline,Quality of life,12 months,Secondary_endpoint
16,NCT01920256,Type 2 Diabetes,Change,baseline,insulin satisfaction,12 months,Secondary_endpoint
17,NCT03840850,Type 2 Diabetes Mellitus,Binary outcome,investigators,intervention,Not Mentioned,Primary_endpoint
18,NCT03840850,Type 2 Diabetes Mellitus,Not Mentioned,Recall,personalised risk information,Not Mentioned,Secondary_endpoint
19,NCT03840850,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,lifestyle changes,Not Mentioned,Secondary_endpoint
20,NCT03840850,Type 2 Diabetes Mellitus,Change,Not Mentioned,self-management behaviour,Not Mentioned,Secondary_endpoint
21,NCT00392678,Type 2 Diabetes,Change,Baseline,HbA1c,Not Mentioned,Primary_endpoint
22,NCT00392678,Type 2 Diabetes,Change in HbA1c,Not Mentioned,Not Mentioned,Not Mentioned,Secondary_endpoint
23,NCT00392678,Type 2 Diabetes,Change,Trends,Fasting Glucose,Not Mentioned,Secondary_endpoint
24,NCT00392678,Type 2 Diabetes,Change in Lipids,Not Mentioned,Not Mentioned,Not Mentioned,Secondary_endpoint
25,NCT00392678,Type 2 Diabetes,Change,Baseline,"C-peptide, Homeostasis Model [",14-week,Secondary_endpoint
26,NCT00392678,Type 2 Diabetes,Change in Insulin,Not Mentioned,"C-peptide, Homeostasis Model [",Not Mentioned,Secondary_endpoint
27,NCT03159221,"Diabetes Mellitus, Type 2|Childhood Obesity",Change in Body,Not Mentioned,status),12 months,Primary_endpoint
28,NCT03159221,"Diabetes Mellitus, Type 2|Childhood Obesity",Not Mentioned,Not Mentioned,Fat (weight status),Not Mentioned,Secondary_endpoint
29,NCT03159221,"Diabetes Mellitus, Type 2|Childhood Obesity",Not Mentioned,Not Mentioned,Not Mentioned,Food intake,Secondary_endpoint
30,NCT03159221,"Diabetes Mellitus, Type 2|Childhood Obesity",Not Mentioned,Not Mentioned,Self-esteem,Not Mentioned,Secondary_endpoint
31,NCT03159221,"Diabetes Mellitus, Type 2|Childhood Obesity",Not Mentioned,Not Mentioned,Quality of Life,Not Mentioned,Secondary_endpoint
32,NCT00485758,Diabetes Mellitus Type 2,Cholesterol,Not Mentioned,Baseline (Bl) in,12 Compared,Primary_endpoint
33,NCT00485758,Diabetes Mellitus Type 2,Change,Not Mentioned,Density Lipoprotein Cholesterol in,12 Compared,Secondary_endpoint
34,NCT00485758,Diabetes Mellitus Type 2,Change,Not Mentioned,Baseline (Bl),12 Compared,Secondary_endpoint
35,NCT03044860,Type2 Diabetes,Not Mentioned,intestinal,Not Mentioned,Not Mentioned,Primary_endpoint
36,NCT03044860,Type2 Diabetes,Not Mentioned,patients,Not Mentioned,Not Mentioned,Primary_endpoint
37,NCT02355145,Type 2 Diabetes Mellitus,Change,Not Mentioned,patients with,Not Mentioned,Primary_endpoint
38,NCT02355145,Type 2 Diabetes Mellitus,Number of years,Not Mentioned,Not Mentioned,Not Mentioned,Secondary_endpoint
39,NCT02355145,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,Not Mentioned,2 time,Secondary_endpoint
40,NCT02355145,Type 2 Diabetes Mellitus,Number of years,Not Mentioned,Not Mentioned,Not Mentioned,Secondary_endpoint
41,NCT02355145,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,used classes of drugs,Not Mentioned,Secondary_endpoint
42,NCT02355145,Type 2 Diabetes Mellitus,Number of years,Not Mentioned,Not Mentioned,Not Mentioned,Secondary_endpoint
43,NCT01257087,Type 2 Diabetes Mellitus|Obesity,HbA1c of,Percentage,Fasting Blood Glucose,Not Mentioned,Primary_endpoint
44,NCT01257087,Type 2 Diabetes Mellitus|Obesity,Percentage,Reduction,Doses/Number of Diabetes Medications Used Preoperatively,Not Mentioned,Secondary_endpoint
45,NCT01257087,Type 2 Diabetes Mellitus|Obesity,Number of Participants,Not Mentioned,Microvascular Events,Not Mentioned,Secondary_endpoint
46,NCT03130894,Type2 Diabetes,Not Mentioned,Not Mentioned,Not Mentioned,Not Mentioned,Primary_endpoint
47,NCT02440555,Type 2 Diabetes,Not Mentioned,Not Mentioned,Not Mentioned,Not Mentioned,Primary_endpoint
48,NCT02440555,Type 2 Diabetes,Not Mentioned,Not Mentioned,Not Mentioned,Not Mentioned,Secondary_endpoint
49,NCT02440555,Type 2 Diabetes,Not Mentioned,cost,screening accessibility to population from the priority health area,Not Mentioned,Secondary_endpoint
50,NCT02440555,Type 2 Diabetes,Not Mentioned,Not Mentioned,numbers of patients screened by self-administered questionnaire,Not Mentioned,Secondary_endpoint
51,NCT02327429,Type 2 Diabetes,Change in Energy,Not Mentioned,Not Mentioned,3-day Food Record),Primary_endpoint
52,NCT02327429,Type 2 Diabetes,Change in Carbohydrate,Not Mentioned,Not Mentioned,3-day Food Record),Primary_endpoint
53,NCT02327429,Type 2 Diabetes,Change in Protein,Not Mentioned,Not Mentioned,3-day Food Record),Primary_endpoint
54,NCT02327429,Type 2 Diabetes,Change,Not Mentioned,Food Record),Not Mentioned,Primary_endpoint
55,NCT02327429,Type 2 Diabetes,Change in Saturated,Not Mentioned,Not Mentioned,3-day Food Record),Primary_endpoint
56,NCT02327429,Type 2 Diabetes,Change,Not Mentioned,Dietary Fibre Intake (3-day Food Record),Not Mentioned,Primary_endpoint
57,NCT02327429,Type 2 Diabetes,Change,Not Mentioned,Added Sucrose Intake (3-day Food Record),Not Mentioned,Primary_endpoint
58,NCT02327429,Type 2 Diabetes,Change in Sodium,Not Mentioned,Not Mentioned,3-day Food Record),Primary_endpoint
59,NCT02327429,Type 2 Diabetes,Change in Calcium,Not Mentioned,Not Mentioned,3-day Food Record),Primary_endpoint
60,NCT02327429,Type 2 Diabetes,Change in Cholesterol,Not Mentioned,Not Mentioned,3-day Food Record),Primary_endpoint
61,NCT02327429,Type 2 Diabetes,Change in Hemoglobin,Not Mentioned,Not Mentioned,Not Mentioned,Secondary_endpoint
62,NCT02327429,Type 2 Diabetes,Change in Body,Not Mentioned,Not Mentioned,Not Mentioned,Secondary_endpoint
63,NCT02327429,Type 2 Diabetes,Change in Waist,Not Mentioned,Not Mentioned,Not Mentioned,Secondary_endpoint
64,NCT02327429,Type 2 Diabetes,Change,Not Mentioned,Fasting Triglyceride,Not Mentioned,Secondary_endpoint
65,NCT02327429,Type 2 Diabetes,Change,Not Mentioned,Fasting Total,Not Mentioned,Secondary_endpoint
66,NCT02327429,Type 2 Diabetes,Change,Not Mentioned,Fasting Low-density Lipoprotein Cholesterol,Not Mentioned,Secondary_endpoint
67,NCT02327429,Type 2 Diabetes,Change,Not Mentioned,Fasting High-density Lipoprotein Cholesterol,Not Mentioned,Secondary_endpoint
68,NCT03259321,Type2 Diabetes,Not Mentioned,Not Mentioned,Not Mentioned,Not Mentioned,Primary_endpoint
69,NCT03259321,Type2 Diabetes,Not Mentioned,Not Mentioned,polyunsaturated fatty acids intake,Not Mentioned,Secondary_endpoint
70,NCT04016584,Type2 Diabetes,Not Mentioned,Not Mentioned,"insulin education program, Diabetes",Not Mentioned,Primary_endpoint
71,NCT04016584,Type2 Diabetes,Not Mentioned,Not Mentioned,self management evaluated,Not Mentioned,Secondary_endpoint
72,NCT04016584,Type2 Diabetes,Not Mentioned,Not Mentioned,Insulin,Not Mentioned,Secondary_endpoint
73,NCT00810823,Type 2 Diabetes,Not Mentioned,remission,Not Mentioned,Not Mentioned,Primary_endpoint
74,NCT01601574,Type 2 Diabetes|Overweight|Obesity,Change in HbA1c,Not Mentioned,Not Mentioned,Not Mentioned,Primary_endpoint
75,NCT01601574,Type 2 Diabetes|Overweight|Obesity,Secondary Endpoints,Not Mentioned,Not Mentioned,Not Mentioned,Secondary_endpoint
76,NCT01601574,Type 2 Diabetes|Overweight|Obesity,Secondary Endpoints,Not Mentioned,Not Mentioned,Not Mentioned,Secondary_endpoint
77,NCT01601574,Type 2 Diabetes|Overweight|Obesity,Secondary Endpoints,Not Mentioned,Not Mentioned,Not Mentioned,Secondary_endpoint
78,NCT01601574,Type 2 Diabetes|Overweight|Obesity,Secondary Endpoints,Not Mentioned,Not Mentioned,Not Mentioned,Secondary_endpoint
79,NCT01601574,Type 2 Diabetes|Overweight|Obesity,Secondary Endpoints,Not Mentioned,Not Mentioned,Not Mentioned,Secondary_endpoint
80,NCT01601574,Type 2 Diabetes|Overweight|Obesity,Secondary Endpoints,Not Mentioned,Not Mentioned,Not Mentioned,Secondary_endpoint
81,NCT01601574,Type 2 Diabetes|Overweight|Obesity,Secondary Endpoints,Not Mentioned,Not Mentioned,Not Mentioned,Secondary_endpoint
82,NCT01601574,Type 2 Diabetes|Overweight|Obesity,Secondary Endpoints,Not Mentioned,Not Mentioned,Not Mentioned,Secondary_endpoint
83,NCT03243136,Type2 Diabetes,Not Mentioned,Not Mentioned,Not Mentioned,Not Mentioned,Primary_endpoint
84,NCT01021865,Coronary Artery Disease|Diabetes Mellitus Type 2,Not Mentioned,Not Mentioned,Not Mentioned,Not Mentioned,Primary_endpoint
85,NCT01021865,Coronary Artery Disease|Diabetes Mellitus Type 2,Not Mentioned,Not Mentioned,Not Mentioned,Not Mentioned,Secondary_endpoint
86,NCT01055652,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with,Not Mentioned,Primary_endpoint
87,NCT01055652,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,Japanese patients with,Not Mentioned,Secondary_endpoint
88,NCT01055652,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,"AUC0-t, tmax,",Not Mentioned,Secondary_endpoint
89,NCT04005261,Type 2 Diabetes Treated With Insulin,Not Mentioned,Not Mentioned,fasting C-peptide concentrations,Not Mentioned,Primary_endpoint
90,NCT04005261,Type 2 Diabetes Treated With Insulin,Correlations of,C,patients characteristics,Not Mentioned,Primary_endpoint
91,NCT00612794,Type 2 Diabetes,Not Mentioned,Not Mentioned,Not Mentioned,Not Mentioned,Primary_endpoint
92,NCT00612794,Type 2 Diabetes,Not Mentioned,Not Mentioned,pharmacokinetics of exenatide administered once weekly by SC injection,Not Mentioned,Secondary_endpoint
93,NCT00612794,Type 2 Diabetes,HbA1c,Not Mentioned,postprandial glucose concentrations,Not Mentioned,Secondary_endpoint
94,NCT01727349,Type 2 Diabetes,Measure,Not Mentioned,Not Mentioned,Not Mentioned,Primary_endpoint
95,NCT00239187,Type 2 Diabetes,Not Mentioned,Not Mentioned,G1,Not Mentioned,Primary_endpoint
96,NCT00239187,Type 2 Diabetes,Not Mentioned,Not Mentioned,G1,Not Mentioned,Secondary_endpoint
97,NCT01073020,Type 2 Diabetes Mellitus|Obesity,Not Mentioned,Not Mentioned,HbA1c,Not Mentioned,Primary_endpoint
98,NCT01073020,Type 2 Diabetes Mellitus|Obesity,"Control, as",Not Mentioned,Not Mentioned,Not Mentioned,Secondary_endpoint
99,NCT01073020,Type 2 Diabetes Mellitus|Obesity,Cardiovascular Risk,Not Mentioned,Not Mentioned,Not Mentioned,Secondary_endpoint
100,NCT01249677,Type 2 Diabetes,Improvements,Not Mentioned,Not Mentioned,Not Mentioned,Primary_endpoint
101,NCT01085292,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,patients with,Not Mentioned,Primary_endpoint
102,NCT01085292,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,patients with,Not Mentioned,Secondary_endpoint
103,NCT01182935,Type 2 Diabetes,Number of subjects,Not Mentioned,Not Mentioned,Not Mentioned,Primary_endpoint
104,NCT01182935,Type 2 Diabetes,Not Mentioned,serum,blood glucose levels,Not Mentioned,Secondary_endpoint
105,NCT02205996,Type 2 Diabetes Mellitus,2000,Not Mentioned,C-reactive protein),Not Mentioned,Secondary_endpoint
106,NCT00240253,Type 2 Diabetes Mellitus,Not Mentioned,safety,regimen of insulin glargine in subjects with,Not Mentioned,Primary_endpoint
107,NCT00240253,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,patient-reported outcomes.,Not Mentioned,Secondary_endpoint
108,NCT00982371,Type 2 Diabetes Mellitus,"Calcium, vitamin",Not Mentioned,total body; physical activity,Not Mentioned,Secondary_endpoint
109,NCT04031417,Type 2 Diabetes,Not Mentioned,Not Mentioned,rank test,Not Mentioned,Primary_endpoint
110,NCT01284465,Type 2 Diabetes,Not Mentioned,Not Mentioned,self-management behaviors,Not Mentioned,Secondary_endpoint
111,NCT02226822,Type 2 Diabetes Mellitus,Classes of diabetic,changes,Not Mentioned,3 years,Primary_endpoint
112,NCT02226822,Type 2 Diabetes Mellitus,Not Mentioned,baseline,blood glucose target goals,Not Mentioned,Secondary_endpoint
113,NCT02226822,Type 2 Diabetes Mellitus,Not Mentioned,baseline,Blood glucose level change from,Not Mentioned,Secondary_endpoint
114,NCT02226822,Type 2 Diabetes Mellitus,change,baseline,Body,Not Mentioned,Secondary_endpoint
115,NCT02226822,Type 2 Diabetes Mellitus,Not Mentioned,baseline,Blood pressure,Not Mentioned,Secondary_endpoint
116,NCT02226822,Type 2 Diabetes Mellitus,Not Mentioned,baseline,Not Mentioned,Not Mentioned,Secondary_endpoint
117,NCT02226822,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,Incidence,Not Mentioned,Secondary_endpoint
118,NCT02226822,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,Hypoglycemia,Not Mentioned,Secondary_endpoint
119,NCT02226822,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,physical activity level,Not Mentioned,Secondary_endpoint
120,NCT02226822,Type 2 Diabetes Mellitus,Not Mentioned,Initiation,patients using insulin,Not Mentioned,Secondary_endpoint
121,NCT02226822,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,Switching of anti-diabetic medications,Not Mentioned,Secondary_endpoint
122,NCT02226822,Type 2 Diabetes Mellitus,Not Mentioned,line,Not Mentioned,Not Mentioned,Secondary_endpoint
123,NCT02226822,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,Incidence,Not Mentioned,Secondary_endpoint
124,NCT01869608,Type 2 Diabetes,Not Mentioned,Not Mentioned,Diagnosis of abnormal glucose tolerance,Not Mentioned,Primary_endpoint
125,NCT01184768,Type 2 Diabetes,Number of subjects,Not Mentioned,Not Mentioned,Not Mentioned,Primary_endpoint
126,NCT01184768,Type 2 Diabetes,Number of subjects,Not Mentioned,Not Mentioned,Not Mentioned,Secondary_endpoint
127,NCT01184768,Type 2 Diabetes,Number of subjects,Not Mentioned,Not Mentioned,Not Mentioned,Secondary_endpoint
128,NCT01184768,Type 2 Diabetes,Not Mentioned,Not Mentioned,D status on glucose tolerance,Not Mentioned,Secondary_endpoint
129,NCT01010035,Type 2 Diabetes Mellitus,Not Mentioned,patients,Not Mentioned,Not Mentioned,Primary_endpoint
130,NCT01237301,Type 2 Diabetes,Change in Hemoglobin,Not Mentioned,Not Mentioned,Not Mentioned,Primary_endpoint
131,NCT01237301,Type 2 Diabetes,Not Mentioned,Not Mentioned,Diurnal Median Curve),Not Mentioned,Secondary_endpoint
132,NCT01237301,Type 2 Diabetes,Change,Baseline,CGM Glucose,Not Mentioned,Secondary_endpoint
133,NCT01088711,Type 2 Diabetes (T2D),Number of Participants,Not Mentioned,Not Mentioned,Not Mentioned,Primary_endpoint
134,NCT01088711,Type 2 Diabetes (T2D),Number of Participants,Not Mentioned,Not Mentioned,Not Mentioned,Primary_endpoint
135,NCT01088711,Type 2 Diabetes (T2D),Not Mentioned,Not Mentioned,After Day 15,Not Mentioned,Secondary_endpoint
136,NCT01088711,Type 2 Diabetes (T2D),Not Mentioned,Not Mentioned,After Day 22,Not Mentioned,Secondary_endpoint
137,NCT01088711,Type 2 Diabetes (T2D),Not Mentioned,Not Mentioned,Active Glucagon-like Peptide-1 (GLP-1),Not Mentioned,Secondary_endpoint
138,NCT01088711,Type 2 Diabetes (T2D),Not Mentioned,Not Mentioned,Total GLP-1 Concentration,Not Mentioned,Secondary_endpoint
139,NCT01088711,Type 2 Diabetes (T2D),Not Mentioned,Not Mentioned,Plasma Glucose,Not Mentioned,Secondary_endpoint
140,NCT03214380,Type 2 Diabetes Mellitus,Change,Baseline,Not Mentioned,Week 26,Primary_endpoint
141,NCT03214380,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,During Mixed-Meal Tolerance Test (MMTT),Not Mentioned,Secondary_endpoint
142,NCT03214380,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,Not Mentioned,2-hour PPG,Secondary_endpoint
143,NCT03214380,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,Rate of Severe Hypoglycemia,Not Mentioned,Secondary_endpoint
144,NCT03214380,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,Rate of Documented Symptomatic Hypoglycemia,Not Mentioned,Secondary_endpoint
145,NCT03214380,Type 2 Diabetes Mellitus,Change,Baseline,Not Mentioned,Week 26,Secondary_endpoint
146,NCT03214380,Type 2 Diabetes Mellitus,Change,Baseline,Not Mentioned,Week 26,Secondary_endpoint
147,NCT03214380,Type 2 Diabetes Mellitus,Change,Baseline,Not Mentioned,Week 26,Secondary_endpoint
148,NCT03214380,Type 2 Diabetes Mellitus,Change,Baseline,Questionnaire (ITSQ) Regimen Inconvenience Domain Score at,Week 26,Secondary_endpoint
149,NCT03214380,Type 2 Diabetes Mellitus,Change,Baseline,Lifestyle Flexibility Domain Score at,Week 26,Secondary_endpoint
150,NCT03214380,Type 2 Diabetes Mellitus,Number of Participants,Not Mentioned,Not Mentioned,<7%,Secondary_endpoint
151,NCT02322762,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,real-world setting.,Not Mentioned,Primary_endpoint
152,NCT02322762,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,blood pressure.,Not Mentioned,Secondary_endpoint
153,NCT02322762,Type 2 Diabetes Mellitus,Changes,Not Mentioned,Not Mentioned,Not Mentioned,Secondary_endpoint
154,NCT02322762,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,Incidence,Not Mentioned,Secondary_endpoint
155,NCT02322762,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,Quality of Life,Not Mentioned,Secondary_endpoint
156,NCT02322762,Type 2 Diabetes Mellitus,Use of Healthcare,Not Mentioned,Not Mentioned,Not Mentioned,Secondary_endpoint
157,NCT00888836,Type 2 Diabetes,Not Mentioned,mellitus,total remission of type,2 diabetes,Primary_endpoint
158,NCT00888836,Type 2 Diabetes,Secondary endpoints,Not Mentioned,quality of life,Not Mentioned,Secondary_endpoint
159,NCT03447275,"Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency",Not Mentioned,Not Mentioned,serum vitamin B12 levels between cases,Not Mentioned,Primary_endpoint
160,NCT03447275,"Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency",Not Mentioned,Not Mentioned,serum vitamin,Not Mentioned,Primary_endpoint
161,NCT03447275,"Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency",Not Mentioned,Not Mentioned,serum vitamin B6 concentrations,Not Mentioned,Primary_endpoint
162,NCT03447275,"Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency",Not Mentioned,Not Mentioned,serum vitamin B12 between patients with,Not Mentioned,Secondary_endpoint
163,NCT03447275,"Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency",Not Mentioned,urine,patients with,Not Mentioned,Secondary_endpoint
164,NCT03447275,"Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency",Not Mentioned,urine,patients with,Not Mentioned,Secondary_endpoint
165,NCT03447275,"Diabetes Mellitus, Type 2|Vitamin B 12 Deficiency|Vitamin B 6 Deficiency",Not Mentioned,urine,vascular risk,Not Mentioned,Secondary_endpoint
166,NCT00451620,Type 2 Diabetes,Not Mentioned,Not Mentioned,postprandial glucose levels in elderly people with,Not Mentioned,Primary_endpoint
167,NCT01845064,Diabetes Type 2,Not Mentioned,Not Mentioned,pharmacokinetic of DM199 after single,Not Mentioned,Primary_endpoint
168,NCT01845064,Diabetes Type 2,Not Mentioned,patients,Not Mentioned,Not Mentioned,Secondary_endpoint
169,NCT01845064,Diabetes Type 2,Not Mentioned,Not Mentioned,Assess formation of ADA,Not Mentioned,Secondary_endpoint
170,NCT01845064,Diabetes Type 2,Not Mentioned,Not Mentioned,Determine changes,Not Mentioned,Secondary_endpoint
171,NCT02104804,Type 2 Diabetes Mellitus,Change in HbA1c,Baseline,Not Mentioned,Week 24,Primary_endpoint
172,NCT02104804,Type 2 Diabetes Mellitus,Change in Postprandial,Baseline,Not Mentioned,Week 24,Secondary_endpoint
173,NCT02104804,Type 2 Diabetes Mellitus,Analysis of Change,Baseline,Not Mentioned,Week 24,Secondary_endpoint
174,NCT02104804,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,Therapeutic Glycaemic Response of HbA1c,Not Mentioned,Secondary_endpoint
175,NCT02104804,Type 2 Diabetes Mellitus,Change,Baseline,Average of Weeks 20,Week 24,Secondary_endpoint
176,NCT02104804,Type 2 Diabetes Mellitus,Analysis of Change,Not Mentioned,Total Daily Dose of Insulin From Baseline,Week 24,Secondary_endpoint
177,NCT00787670,Obesity|Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,loss decreases the risk of CVD,Not Mentioned,Primary_endpoint
178,NCT00787670,Obesity|Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,risk of CVD in morbidly obese subjects with T2DM.,Not Mentioned,Secondary_endpoint
179,NCT01933256,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,Not Mentioned,Not Mentioned,Primary_endpoint
180,NCT03406910,Type 2 Diabetes|Heart Diseases,Not Mentioned,Not Mentioned,Not Mentioned,Not Mentioned,Primary_endpoint
181,NCT01649466,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,patients reaching HbA1c below 7.0% without confirmed hypoglycemia,Not Mentioned,Primary_endpoint
182,NCT01649466,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,Rate of confirmed hypoglycemic events,Not Mentioned,Primary_endpoint
183,NCT01649466,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,blood glucose target (HbA1c below 7.0%),Not Mentioned,Secondary_endpoint
184,NCT01649466,Type 2 Diabetes Mellitus,Change,baseline,Not Mentioned,24 weeks,Secondary_endpoint
185,NCT01649466,Type 2 Diabetes Mellitus,Change,baseline,Not Mentioned,24 weeks,Secondary_endpoint
186,NCT01649466,Type 2 Diabetes Mellitus,Change,baseline,Medication (TSQM-9),24 week,Secondary_endpoint
187,NCT03464812,Type2 Diabetes,Not Mentioned,Not Mentioned,self-care,Not Mentioned,Secondary_endpoint
188,NCT03464812,Type2 Diabetes,Not Mentioned,Not Mentioned,referring provider satisfaction,Not Mentioned,Secondary_endpoint
189,NCT02501876,Alzheimer´s Disease|Diabetes Mellitus Type 2,Not Mentioned,Not Mentioned,Alzheimer's disease (AD),Not Mentioned,Primary_endpoint
190,NCT02501876,Alzheimer´s Disease|Diabetes Mellitus Type 2,Not Mentioned,Not Mentioned,Alzheimer's disease (AD),Not Mentioned,Secondary_endpoint
191,NCT03341117,"Diabetes Mellitus, Type 2|Antioxidant Enzyme System",Modification,Not Mentioned,Not Mentioned,Not Mentioned,Primary_endpoint
192,NCT03341117,"Diabetes Mellitus, Type 2|Antioxidant Enzyme System",Modification,profile,administration of Acetylsalicylic Acid,Not Mentioned,Secondary_endpoint
193,NCT03341117,"Diabetes Mellitus, Type 2|Antioxidant Enzyme System",Not Mentioned,Modification,administration of Acetylsalicylic Acid,Not Mentioned,Secondary_endpoint
194,NCT03341117,"Diabetes Mellitus, Type 2|Antioxidant Enzyme System",Modification,Not Mentioned,administration of Acetylsalicylic acid,Not Mentioned,Secondary_endpoint
195,NCT04214600,Type 2 Diabetes|Depression,Change of Glycated,Not Mentioned,Cognitive Behavioral Therapy Sessions,Not Mentioned,Primary_endpoint
196,NCT04214600,Type 2 Diabetes|Depression,Change of Depression,Not Mentioned,Depression Index,Not Mentioned,Secondary_endpoint
197,NCT01037647,Type 2 Diabetes,Not Mentioned,Not Mentioned,VLDL-TG production,Not Mentioned,Primary_endpoint
198,NCT01037647,Type 2 Diabetes,Not Mentioned,Not Mentioned,VLDL-TG oxidation,Not Mentioned,Secondary_endpoint
199,NCT01037647,Type 2 Diabetes,Not Mentioned,Not Mentioned,VLDL-TG subcutaneous adipose,Not Mentioned,Secondary_endpoint
200,NCT00103935,Type 2 Diabetes Mellitus,Not Mentioned,safety,pharmacokinetics of exenatide long-acting release (LAR) administered weekly by subcutaneous (SC),Not Mentioned,Primary_endpoint
201,NCT00103935,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,parameters of exenatide LAR administered weekly,Not Mentioned,Secondary_endpoint
202,NCT00103935,Type 2 Diabetes Mellitus,Change in HbA1c,Baseline,Not Mentioned,Not Mentioned,Secondary_endpoint
203,NCT00103935,Type 2 Diabetes Mellitus,Change,Baseline,Not Mentioned,27),Secondary_endpoint
204,NCT00103935,Type 2 Diabetes Mellitus,Change,Baseline,Not Mentioned,27),Secondary_endpoint
205,NCT00103935,Type 2 Diabetes Mellitus,Change,Not Mentioned,seven-point glucose concentrations from Baseline,14 and Week 15,Secondary_endpoint
206,NCT00525330,Type 2 Diabetes,Not Mentioned,Not Mentioned,Not Mentioned,Not Mentioned,Primary_endpoint
207,NCT00525330,Type 2 Diabetes,Not Mentioned,Not Mentioned,fasting plasma glucose (FPG)-lowering effect of KRP-104 in patients with,Not Mentioned,Secondary_endpoint
208,NCT00525330,Type 2 Diabetes,Not Mentioned,setting,insulin sensitivity (homeostasis model index,Not Mentioned,Secondary_endpoint
209,NCT01977560,Type 2 Diabetes,Control,Not Mentioned,Not Mentioned,Not Mentioned,Primary_endpoint
210,NCT01977560,Type 2 Diabetes,Neuronal Function,Not Mentioned,Not Mentioned,Not Mentioned,Secondary_endpoint
211,NCT01278823,Obesity|Type 2 Diabetes,Not Mentioned,patients,Not Mentioned,Not Mentioned,Primary_endpoint
212,NCT01278823,Obesity|Type 2 Diabetes,Not Mentioned,patients,pancreatic beta cell,Not Mentioned,Secondary_endpoint
213,NCT01580475,Type 2 Diabetes,Changes,baseline,retraining (9 months),3 months,Primary_endpoint
214,NCT01580475,Type 2 Diabetes,Not Mentioned,Evaluation,Not Mentioned,Not Mentioned,Secondary_endpoint
215,NCT01580475,Type 2 Diabetes,Not Mentioned,Not Mentioned,Not Mentioned,Not Mentioned,Secondary_endpoint
216,NCT00108004,Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus,Not Mentioned,safety,Not Mentioned,Not Mentioned,Primary_endpoint
217,NCT00108004,Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,Not Mentioned,Not Mentioned,Primary_endpoint
218,NCT02222350,Type 2 Diabetes Mellitus,change,Not Mentioned,blood glucose,Not Mentioned,Primary_endpoint
219,NCT02222350,Type 2 Diabetes Mellitus,change,Not Mentioned,blood glucose,Not Mentioned,Secondary_endpoint
220,NCT02222350,Type 2 Diabetes Mellitus,change,Not Mentioned,blood fasting plasma glucose level,Not Mentioned,Secondary_endpoint
221,NCT02222350,Type 2 Diabetes Mellitus,change,Not Mentioned,blood plasma glucose level,Not Mentioned,Secondary_endpoint
222,NCT02222350,Type 2 Diabetes Mellitus,change,Not Mentioned,blood insulin level,Not Mentioned,Secondary_endpoint
223,NCT02222350,Type 2 Diabetes Mellitus,change,Not Mentioned,blood C-peptide level,Not Mentioned,Secondary_endpoint
224,NCT02222350,Type 2 Diabetes Mellitus,change,level,Not Mentioned,Not Mentioned,Secondary_endpoint
225,NCT02222350,Type 2 Diabetes Mellitus,change,Not Mentioned,blood PYY level,Not Mentioned,Secondary_endpoint
226,NCT02222350,Type 2 Diabetes Mellitus,change,Not Mentioned,blood HbA1c level,Not Mentioned,Secondary_endpoint
227,NCT02222350,Type 2 Diabetes Mellitus,change,Not Mentioned,blood glycoalbumin level,Not Mentioned,Secondary_endpoint
228,NCT02222350,Type 2 Diabetes Mellitus,Number of subjects,Not Mentioned,Not Mentioned,Not Mentioned,Secondary_endpoint
229,NCT02222350,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,pharmacokinetic profile of DS-8500a,Not Mentioned,Secondary_endpoint
230,NCT02222350,Type 2 Diabetes Mellitus,change,Not Mentioned,plasma glucose level,Not Mentioned,Secondary_endpoint
231,NCT00922649,Type 2 Diabetes,Not Mentioned,Not Mentioned,Insulin,Week 16,Primary_endpoint
232,NCT00922649,Type 2 Diabetes,Not Mentioned,Ratio,Not Mentioned,Week 16,Primary_endpoint
233,NCT00922649,Type 2 Diabetes,Number of daily,Not Mentioned,Not Mentioned,Week 16,Primary_endpoint
234,NCT00922649,Type 2 Diabetes,Not Mentioned,Not Mentioned,A1C (Hemoglobin A1c),Not Mentioned,Secondary_endpoint
235,NCT00922649,Type 2 Diabetes,CGM Glucose,Not Mentioned,Not Mentioned,Not Mentioned,Secondary_endpoint
236,NCT00922649,Type 2 Diabetes,Change,baseline,16,Not Mentioned,Secondary_endpoint
237,NCT03324776,Type2 Diabetes,Not Mentioned,baseline,Not Mentioned,Not Mentioned,Primary_endpoint
238,NCT03324776,Type2 Diabetes,Not Mentioned,Not Mentioned,patients having HbA1c,Not Mentioned,Secondary_endpoint
239,NCT03324776,Type2 Diabetes,Not Mentioned,Not Mentioned,Blood glucose (BG),Not Mentioned,Secondary_endpoint
240,NCT04163757,Type 2 Diabetes,Not Mentioned,Not Mentioned,Not Mentioned,Not Mentioned,Primary_endpoint
241,NCT00971659,Type 2 Diabetes,Not Mentioned,Not Mentioned,blood glucose excursion (AUCBG0-6h),Not Mentioned,Primary_endpoint
242,NCT00971659,Type 2 Diabetes,Not Mentioned,Not Mentioned,"self-measured 7-point BG profiles, percentage of subjects achieving ADA HbA1c treatment goals, fasting lipid",Not Mentioned,Secondary_endpoint
243,NCT01607294,Hyperlipidemia|Type 2 Diabetes,Not Mentioned,Not Mentioned,LDL-C lowering efficacy of ETC-1002 versus placebo in subjects with,Not Mentioned,Primary_endpoint
244,NCT01607294,Hyperlipidemia|Type 2 Diabetes,Not Mentioned,Not Mentioned,insulin,Not Mentioned,Secondary_endpoint
245,NCT01607294,Hyperlipidemia|Type 2 Diabetes,Not Mentioned,Not Mentioned,Not Mentioned,Not Mentioned,Secondary_endpoint
246,NCT00299871,Type 2 Diabetes,Not Mentioned,baseline,HbA1c,13 weeks,Primary_endpoint
247,NCT00299871,Type 2 Diabetes,Not Mentioned,Fructosamine,"C-peptide, glucagon.",Not Mentioned,Secondary_endpoint
248,NCT00303394,Type 2 Diabetes,Stimulated C peptide,Not Mentioned,insulin,Not Mentioned,Secondary_endpoint
249,NCT00303394,Type 2 Diabetes,Not Mentioned,Not Mentioned,Fasting plasma glucose (FPG),Not Mentioned,Secondary_endpoint
250,NCT00303394,Type 2 Diabetes,Not Mentioned,Not Mentioned,"Serum cytokine levels, CRP",Not Mentioned,Secondary_endpoint
251,NCT00303394,Type 2 Diabetes,Not Mentioned,Not Mentioned,insulin,Not Mentioned,Secondary_endpoint
252,NCT00303394,Type 2 Diabetes,Not Mentioned,Not Mentioned,"subgroup of patients, insulin-sensitivity assessed by clamp",Not Mentioned,Secondary_endpoint
253,NCT00303394,Type 2 Diabetes,Not Mentioned,Not Mentioned,profiles derived from muscle,Not Mentioned,Secondary_endpoint
254,NCT00631774,Type 2 Diabetes|Obesity,Not Mentioned,Not Mentioned,Not Mentioned,Not Mentioned,Primary_endpoint
255,NCT00631774,Type 2 Diabetes|Obesity,Not Mentioned,based,quality of life,Not Mentioned,Secondary_endpoint
256,NCT04072523,Type 2 Diabetes,Not Mentioned,Correlation,Not Mentioned,Not Mentioned,Secondary_endpoint
257,NCT02065544,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,HS-C Reactive Protein,Not Mentioned,Secondary_endpoint
258,NCT02065544,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,Aerobic Fitness,Not Mentioned,Secondary_endpoint
259,NCT00837408,Diabetes|Hypertension,Not Mentioned,Not Mentioned,Not Mentioned,Not Mentioned,Primary_endpoint
260,NCT03909269,Diabetic Nephropathy Type 2|Type2 Diabetes,Not Mentioned,Not Mentioned,total mean glucose from continuous glucose monitoring,Not Mentioned,Primary_endpoint
261,NCT03909269,Diabetic Nephropathy Type 2|Type2 Diabetes,Not Mentioned,Fructosamine,Not Mentioned,Not Mentioned,Secondary_endpoint
262,NCT03909269,Diabetic Nephropathy Type 2|Type2 Diabetes,Not Mentioned,Not Mentioned,HbA1c,Not Mentioned,Secondary_endpoint
263,NCT03909269,Diabetic Nephropathy Type 2|Type2 Diabetes,Not Mentioned,Not Mentioned,Blood volume,Not Mentioned,Secondary_endpoint
264,NCT03909269,Diabetic Nephropathy Type 2|Type2 Diabetes,Coefficient,Not Mentioned,Not Mentioned,Not Mentioned,Secondary_endpoint
265,NCT03909269,Diabetic Nephropathy Type 2|Type2 Diabetes,Not Mentioned,Not Mentioned,Blood Glucose Index,Not Mentioned,Secondary_endpoint
266,NCT03909269,Diabetic Nephropathy Type 2|Type2 Diabetes,Not Mentioned,Not Mentioned,Blood Glucose Index,Not Mentioned,Secondary_endpoint
267,NCT03909269,Diabetic Nephropathy Type 2|Type2 Diabetes,Not Mentioned,Not Mentioned,range below 3.9 mmol/l,Not Mentioned,Secondary_endpoint
268,NCT00477581,Type 2 Diabetes Mellitus,Assessment of,Not Mentioned,Not Mentioned,6-point self-monitored blood glucose (SMBG),Secondary_endpoint
269,NCT00799643,Type 2 Diabetes Mellitus,Change in HbA1c,Compared,Not Mentioned,Not Mentioned,Primary_endpoint
270,NCT00799643,Type 2 Diabetes Mellitus,Change,Baseline,Fasting Glucose,Not Mentioned,Secondary_endpoint
271,NCT00799643,Type 2 Diabetes Mellitus,Not Mentioned,Reduction,HbA1c,Not Mentioned,Secondary_endpoint
272,NCT00799643,Type 2 Diabetes Mellitus,Change in Lipids,Not Mentioned,LDL-C/HDL-C Ratio),Not Mentioned,Secondary_endpoint
273,NCT00799643,Type 2 Diabetes Mellitus,Changes,Not Mentioned,"Differential, High-sensitivity C Reactive Protein (hsCRP)",Not Mentioned,Secondary_endpoint
274,NCT00799643,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,Discontinuation of Study Medication,Not Mentioned,Secondary_endpoint
275,NCT00799643,Type 2 Diabetes Mellitus,"Secretagogue, Metformin",Not Mentioned,Combination Therapy,Not Mentioned,Secondary_endpoint
276,NCT01640873,Type 2 Diabetes,Number of Participants,Not Mentioned,Adverse Events,Not Mentioned,Primary_endpoint
277,NCT01640873,Type 2 Diabetes,Number of Participants,Not Mentioned,Adverse Event,Not Mentioned,Primary_endpoint
278,NCT01640873,Type 2 Diabetes,Not Mentioned,Not Mentioned,Fasting Plasma Glucose (FPG),Not Mentioned,Primary_endpoint
279,NCT01640873,Type 2 Diabetes,Concentrations,Not Mentioned,After Single and Multiple Drug Doses,Not Mentioned,Secondary_endpoint
280,NCT01640873,Type 2 Diabetes,Not Mentioned,Not Mentioned,Weighted,Not Mentioned,Secondary_endpoint
281,NCT01640873,Type 2 Diabetes,Change,Baseline,Not Mentioned,2 Hours Oral Glucose Tolerance Test,Secondary_endpoint
282,NCT01159249,Type 2 Diabetes,Not Mentioned,AEs,Not Mentioned,Not Mentioned,Primary_endpoint
283,NCT01159249,Type 2 Diabetes,Not Mentioned,Not Mentioned,Fasting Plasma Glucose,Not Mentioned,Secondary_endpoint
284,NCT01159249,Type 2 Diabetes,Not Mentioned,Not Mentioned,Fasting Insulin,Not Mentioned,Secondary_endpoint
285,NCT01159249,Type 2 Diabetes,Not Mentioned,Not Mentioned,Fasting C,Not Mentioned,Secondary_endpoint
286,NCT00106808,Type 2 Diabetes Mellitus,Change in HBA1c,baseline,Not Mentioned,Week 24,Primary_endpoint
287,NCT00106808,Type 2 Diabetes Mellitus,Change,baseline,HDL-C,Week 24,Secondary_endpoint
288,NCT00106808,Type 2 Diabetes Mellitus,Change,baseline,Not Mentioned,Not Mentioned,Secondary_endpoint
289,NCT04176276,Diabetic Kidney Disease|Type2 Diabetes,Not Mentioned,Not Mentioned,Serum expression of miR-192,Not Mentioned,Primary_endpoint
290,NCT04176276,Diabetic Kidney Disease|Type2 Diabetes,Not Mentioned,Not Mentioned,Serum expression of miR-25,Not Mentioned,Primary_endpoint
291,NCT04176276,Diabetic Kidney Disease|Type2 Diabetes,Not Mentioned,Urine,Not Mentioned,Not Mentioned,Primary_endpoint
292,NCT04176276,Diabetic Kidney Disease|Type2 Diabetes,Not Mentioned,Urine,Not Mentioned,Not Mentioned,Primary_endpoint
293,NCT03902288,Patients With Type 2 Diabetes (FSG: More Than 7.1 and Not Higher Than 15.8 mmol/L),Not Mentioned,Not Mentioned,Fasting serum glucose measurement,Not Mentioned,Primary_endpoint
294,NCT03902288,Patients With Type 2 Diabetes (FSG: More Than 7.1 and Not Higher Than 15.8 mmol/L),Not Mentioned,Not Mentioned,Serum total antioxidant activity measurement,Not Mentioned,Secondary_endpoint
295,NCT03538743,Type 2 Diabetes Mellitus,Number of Participants,Not Mentioned,All-causality,Not Mentioned,Primary_endpoint
296,NCT03538743,Type 2 Diabetes Mellitus,Number of Participants,Not Mentioned,Laboratory Abnormalities Without Regard to Baseline,Not Mentioned,Primary_endpoint
297,NCT03538743,Type 2 Diabetes Mellitus,Number of Participants,Not Mentioned,Abnormal Vital Signs,Not Mentioned,Primary_endpoint
298,NCT03538743,Type 2 Diabetes Mellitus,Number of Participants,Not Mentioned,Abnormal Electrocardiogram (ECG) Interval,Not Mentioned,Primary_endpoint
299,NCT03538743,Type 2 Diabetes Mellitus,AUC24,Not Mentioned,AUCtau of PF-06882961 on Day 1,14 or 21,Secondary_endpoint
300,NCT03538743,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,Maximum Plasma Concentration (Cmax),14 or 21,Secondary_endpoint
301,NCT03538743,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,Not Mentioned,14 or 21,Secondary_endpoint
302,NCT03538743,Type 2 Diabetes Mellitus,Amount of Unchanged,Not Mentioned,Hours (Ae24),Not Mentioned,Secondary_endpoint
303,NCT03538743,Type 2 Diabetes Mellitus,Not Mentioned,Not Mentioned,Ae24 (%),Not Mentioned,Secondary_endpoint
304,NCT01472185,Type 2 Diabetes Mellitus,Change,Baseline,HbA1c,Week 24,Primary_endpoint
305,NCT01472185,Type 2 Diabetes Mellitus,Change,Baseline,Fasting Serum Glucose,Week 24,Secondary_endpoint
306,NCT01472185,Type 2 Diabetes Mellitus,Percentage of Participants,Not Mentioned,Not Mentioned,Week 24,Secondary_endpoint
307,NCT01472185,Type 2 Diabetes Mellitus,Change,Baseline,Not Mentioned,Week 24,Secondary_endpoint
308,NCT01472185,Type 2 Diabetes Mellitus,Change,Baseline,Not Mentioned,Week 24,Secondary_endpoint
309,NCT01494987,Type 2 Diabetes Mellitus,Change,Baseline,HbA1c,Week 24,Primary_endpoint
310,NCT01494987,Type 2 Diabetes Mellitus,Change,Baseline,Not Mentioned,Week 24,Secondary_endpoint
311,NCT01494987,Type 2 Diabetes Mellitus,Change,Baseline,Fasting Serum Glucose,Week 24,Secondary_endpoint
312,NCT01494987,Type 2 Diabetes Mellitus,Change,Baseline,Not Mentioned,Week 24,Secondary_endpoint
313,NCT02343471,Healthy|Type 2 Diabetes,Not Mentioned,Not Mentioned,Curve (iAUC -15 - 360 min).,Not Mentioned,Primary_endpoint
314,NCT02343471,Healthy|Type 2 Diabetes,Not Mentioned,Not Mentioned,Curve (iAUC -15 - 360 min).,Not Mentioned,Primary_endpoint
315,NCT02343471,Healthy|Type 2 Diabetes,Not Mentioned,Not Mentioned,Curve (AUC -15 - 360 min),Not Mentioned,Secondary_endpoint
316,NCT02343471,Healthy|Type 2 Diabetes,Not Mentioned,Not Mentioned,Curve (AUC -15 - 360 min),Not Mentioned,Secondary_endpoint
317,NCT02343471,Healthy|Type 2 Diabetes,Not Mentioned,Not Mentioned,Curve (AUC -15 - 360 min),Not Mentioned,Secondary_endpoint
318,NCT02343471,Healthy|Type 2 Diabetes,Not Mentioned,Not Mentioned,Curve (AUC -15 - 360 min),Not Mentioned,Secondary_endpoint
319,NCT02343471,Healthy|Type 2 Diabetes,Not Mentioned,Not Mentioned,Curve (AUC -15 - 360 min).,Not Mentioned,Secondary_endpoint
320,NCT01755468,Type 2 Diabetes,Not Mentioned,Baseline,Secretion-Sensitivity Index-2 (ISSI-2).,2 years,Primary_endpoint
321,NCT01755468,Type 2 Diabetes,Not Mentioned,Baseline,Not Mentioned,2-years,Secondary_endpoint
322,NCT04363710,Type 2 Diabetes Mellitus in Obese,Not Mentioned,percentage,HbA1c,Not Mentioned,Primary_endpoint
323,NCT04363710,Type 2 Diabetes Mellitus in Obese,Not Mentioned,liter,Fasting Insulin Level,Not Mentioned,Primary_endpoint
324,NCT04363710,Type 2 Diabetes Mellitus in Obese,Not Mentioned,BMI,Weight,Not Mentioned,Primary_endpoint
325,NCT00562029,Type 2 Diabetes Mellitus,Not Mentioned,Resolution,Not Mentioned,Not Mentioned,Primary_endpoint
